Skip To Main Content
Morales-Barrera R on Muck Rack

Morales-Barrera R

As seen in: National Institutes of Health
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Morales-Barrera

Contact Morales-Barrera, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment - PubMed

|
By Morales-Barrera R
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (618) Issue with article?

Impact of Performance Status on Treatment Outcomes: A Real-World Study of Advanced Urothelial Cancer Treated With Immune Checkpoint Inhibitors

|
By Morales-Barrera R, Diamantopoulos LN, Bilen MA, Hoimes CJ
| National Institutes of Health
doi: 10.1002/cncr.32645. Epub 2019 Dec 12.
Open in Who Shared Issue with article?

The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor.

|
By Morales-Barrera R
| ncbi.nlm.nih.gov
Cancer Treat Rev. 2020 Mar 13;86:102000. doi: 10.1016/j.ctrv.2020.102000. [Epub ahead of print] Abstract Therapeutic options for metastatic bladder cancer (BC) have seen minimal evolution over the past 30 years, with platinum-based chemotherapy remaining the mainstay of standard of care for metastatic BC. Recently, five immune checkpoint inhibitors (ICIs) have been approved by the FDA as second-line therapy, and two ICIs are approved as first-line treatment in selected patients.
Open in Who Shared Issue with article?
See all 3 articles